Market Intelligence, Clinical Progress, and High-Purity Reagents for Transcription-Addicted Oncology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for GTF2E2 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | GTF2E2 Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Theoretical MW Match. |
View GTF2E2 Products |
| Gene Delivery | GTF2E2 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation and overexpression. |
View GTF2E2 Products |
| Benchmark Ab | Anti-GTF2E2 Recombinant Antibody High-affinity positive control for Western Blot, IP, and ELISA. |
View GTF2E2 Products |
| Validator | GTF2E2 siRNA Set Target-specific knockdown verification in cell-based assays. |
View GTF2E2 Products |
| Related Target A | GTF2E1 (TFIIE Alpha) Obligate partner in the TFIIE heterotetramer; essential for functional complex assembly. |
View GTF2E1 Products |
| Related Target B | GTF2H1 (TFIIH Core Subunit) Downstream partner recruited by TFIIE to initiate promoter melting. |
View GTF2H1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Reconstituting the active TFIIE α2β2 heterotetramer in vitro | Co-expressed or highly pure individual GTF2E2 and GTF2E1 proteins available with verified sequence integrity. |
| High-throughput screening for PPI (Protein-Protein Interaction) inhibitors | Tag-specific (His/GST/Flag) recombinant GTF2E2 variants designed for robust AlphaLISA or TR-FRET assays. |
| Lack of Controls | Sequence-verified benchmark antibodies and positive control expression constructs included. |
| False Positives | Validated siRNA pools included for target-specific knockdown and orthologous validation. |
Live GTF2E2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for transcriptional machinery therapeutics is intensifying, with major players shifting focus from traditional global kinase inhibition to selective transcription factor complex disruption (such as TFIIE-TFIIH or TFIIE-Pol II interactions). As first-generation general transcription inhibitors reveal toxicity profiles, the next wave of R&D is targeting GTF2E2 (TFIIE Beta) to selectively disrupt oncogenic transcription-addicted states in MYC-driven and triple-negative breast cancers (TNBC).
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (PPI Inhibitor) | Academic Consortia, Biotech Startups | Solid Tumors (TNBC, Myc-amplified) | In vitro binding assays requiring highly pure, non-denatured recombinant GTF2E2. |
| PROTAC / Degrader | Targeted Protein Degradation (TPD) Pioneers | Hematological Malignancies | Ubiquitination assays requiring stable, sequence-verified GTF2E2 protein as substrate. |
| RNA Therapeutics (siRNA/ASO) | RNAi Therapeutics Developers | Advanced Refractory Solid Tumors | Lentivirus-driven rescue lines and validated siRNA knockdown comparison panels. |